Aptinyx (NASDAQ: APTX)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-08 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.280 | -0.260 | 0.0200 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Aptinyx (NASDAQ: APTX) through any online brokerage.
Other companies in Aptinyx’s space includes: Monopar Therapeutics (NASDAQ:MNPR), Cyclacel Pharmaceuticals (NASDAQ:CYCC), Calithera Biosciences (NASDAQ:CALA), ABVC BioPharma (NASDAQ:ABVC) and Indaptus Therapeutics (NASDAQ:INDP).
The latest price target for Aptinyx (NASDAQ: APTX) was reported by Cowen & Co. on Tuesday, August 16, 2022. The analyst firm set a price target for 0.00 expecting APTX to fall to within 12 months (a possible -100.00% downside). 11 analyst firms have reported ratings in the last year.
The stock price for Aptinyx (NASDAQ: APTX) is $0.3384 last updated Today at August 18, 2022, 4:59 PM UTC.
There are no upcoming dividends for Aptinyx.
Aptinyx’s Q3 earnings are confirmed for Tuesday, November 8, 2022.
There is no upcoming split for Aptinyx.
Aptinyx is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.